Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Rocatinlimab by Kyowa Kirin for Asthma: Likelihood of Approval
Rocatinlimab is under clinical development by Kyowa Kirin and currently in Phase II for Asthma. According to GlobalData, Phase II...
Rocatinlimab by Kyowa Kirin for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
Rocatinlimab is under clinical development by Kyowa Kirin and currently in Phase III for Atopic Dermatitis (Atopic Eczema). According to...
Rocatinlimab by Kyowa Kirin for Prurigo: Likelihood of Approval
Rocatinlimab is under clinical development by Kyowa Kirin and currently in Phase III for Prurigo. According to GlobalData, Phase III...
Risk adjusted net present value: What is the current valuation of Amgen's Rocatinlimab?
Rocatinlimab is a monoclonal antibody commercialized by Amgen, with a leading Phase III program in Atopic Dermatitis (Atopic Eczema). According...
Risk adjusted net present value: What is the current valuation of Kyowa Kirin's Rocatinlimab?
Rocatinlimab is a monoclonal antibody commercialized by Kyowa Kirin, with a leading Phase III program in Atopic Dermatitis (Atopic Eczema)....
Risk adjusted net present value: What is the current valuation of Amgen's Rocatinlimab?
Rocatinlimab is a monoclonal antibody commercialized by Amgen, with a leading Phase III program in Atopic Dermatitis (Atopic Eczema). According...